SciClone Pharmaceuticals IPO Initiation: A Hard Sell

SciClone is pre-marketing a Hong Kong IPO to raise $500 million, according to press reports. Overall, on a fundamental basis, we are inclined to give this IPO a pass.

SUMMARY(Sign Up to Access)

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

• Unlimited Research Summaries
• Personalised Alerts
• Custom Watchlists
• Company Data & News
• Events & Webinars

Trusted by:

SMARTKARMA PREVIEW PASS

Sign Up with LinkedIn

or

First NameLast nameEmail

Sign Up with EmailBy signing up, you agree to our
Terms of Use and Privacy Policy.

Trusted by:

Already have an account? Sign In Now